pharmacogenomics Flashcards
Pharmacogenetics
Study of genetic causes of individual variations with drug response
Pharmacogenomics
Study of genetic determinant of drug efficacy and toxicity
Variation in response can be caused by
Difference in concentration at drug site-PK variability
Different response to same conc- PD variability
Variation in response could be due to
Single nucleotide polymorphisms
insertions, deletions
How do SNPs and indels cause these variations
By changing base sequence of DNA which may result in change in amino acid sequence
Enzymes, drug transporters,and receptors are made of proteins are made of proteins hence a change in protein can change how drug is metaboloised
What is PK variability
Variability in the amount of drug delivered to receptor
Some processes of PK
Metabolism process- converting drug o water soluble form
Enzymes- can convert inactive substances into active forms
PK variability occurs because
Poor metabolizer
ultraRapid metabolizer
Enzyme deficiency
Drug transporter variability
Drug metabolizing enzymes divided into
phase 1- enzymes that add or remove functional groups in a substrate through oxidation, reduction, hydrolysis
Phase 2- Enzymes that transfer moieties from co factor to substrate
Most important phase 1 enzyme
cytochrome p450
CYP genes are highly
Polymorphic which can produce abolished, reduced or enhanced enzyme activity
Classification of 4 phenotypes due to level of CYP enzymes
Poor metabolizer - enzyme abolished
Intermediate- reduced
extensive- normal
ultrarapid-enhanced
A poor metabolizer
Requires low dose so it doesnt accumulate in system
A rapid metabolizer
Requires high doses so therapeutic effect can be met
CYP polymorphisms mainly found in
CYP2D6
CYP2C9
CYP2C19
Polymorphic phase one enzyme
plasma cholinesterase
Clopidogrel is a
Prodrug
Clopidogrel binds to
ADP receptor
This enzyme helps metabolise clopidogrel
CYP2D19
Loss of function alleles of CYP2C19
*2 and *3
CYP2C19 loss of function alleles have been associated with
adverse ischemic events
CYYP2C19 gain of function allele
CYP2C19*17
Gain of function allele is thought to result in
higher cata;ytic activity
Decreased risk of ischemic events
Increased risk of bleeding
Warfarin used for
Thromboembolism
prevents systemic embolism in people with atrial fibrillation
Warfarin has a narrow
Therapeutic index
Major enzyme that metabolizes warfarin
CYP2C9
VCORC1 gene, the target of warfarin
Impairment of warfarin therapy by
Loss of function genes
VKORCI MUTATION
warfarin tretment resistance
Adverse ischemic events
Dabigatran etexilate is prodrug for
Dabigatran
dabigatran is as effective as this for stroke prevention
Standard dose warfarin
Decrease in Trough concentrations of dabigatran caused by
SNP in CES 1 gene
CES 1 codes for
liver carboxylesterase 1 responsible for conversion of dabigatran etixilate to dabigatran